Oliwier R. Dulawa, Shane M. Coyle, Fiona Walsh, Trinidad Velasco-Torrijos
{"title":"Beyond FimH: Diversity and Relevance of Carbohydrate-Binding Fimbrial Proteins in Escherichia coli","authors":"Oliwier R. Dulawa, Shane M. Coyle, Fiona Walsh, Trinidad Velasco-Torrijos","doi":"10.1002/cbic.202500433","DOIUrl":null,"url":null,"abstract":"<p><i>Escherichia coli</i> (<i>E. coli</i>) is responsible for multiple diseases in humans and animals. Many of them are treated with antibiotics; however, the need for new therapies has led to research in alternative treatments. One such approach involves preventing the adherence of <i>E. coli</i> to host cells by inhibiting their adhesins. Adherence is a crucial step of pathogenesis, and bacterial lectins that recognize host glycans play major roles in host cell adhesion. In fact, lectins are the most common bacterial adhesins. The various pathogenic and nonpathogenic <i>E. coli</i> strains express a multitude of lectins, many of which are found on <i>E. coli</i> fimbriae. Current research on lectin inhibition using glycomimetics has produced many mannose-based inhibitors of the uropathogenic <i>E. coli</i> fimbrial lectin FimH. However, only a limited number of synthetic inhibitors are reported for other lectins. In this review, many other cell surface adhesins of <i>E. coli</i> are discussed, focusing on fimbrial lectins. The types of <i>E. coli</i> strains they are found in, their carbohydrate targets, and their binding sites are also discussed. This review aims to highlight the many lectins that can become therapeutic targets to treat <i>E. coli</i> infections in addition to FimH.</p>","PeriodicalId":140,"journal":{"name":"ChemBioChem","volume":"26 17","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemBioChem","FirstCategoryId":"99","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202500433","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Escherichia coli (E. coli) is responsible for multiple diseases in humans and animals. Many of them are treated with antibiotics; however, the need for new therapies has led to research in alternative treatments. One such approach involves preventing the adherence of E. coli to host cells by inhibiting their adhesins. Adherence is a crucial step of pathogenesis, and bacterial lectins that recognize host glycans play major roles in host cell adhesion. In fact, lectins are the most common bacterial adhesins. The various pathogenic and nonpathogenic E. coli strains express a multitude of lectins, many of which are found on E. coli fimbriae. Current research on lectin inhibition using glycomimetics has produced many mannose-based inhibitors of the uropathogenic E. coli fimbrial lectin FimH. However, only a limited number of synthetic inhibitors are reported for other lectins. In this review, many other cell surface adhesins of E. coli are discussed, focusing on fimbrial lectins. The types of E. coli strains they are found in, their carbohydrate targets, and their binding sites are also discussed. This review aims to highlight the many lectins that can become therapeutic targets to treat E. coli infections in addition to FimH.
期刊介绍:
ChemBioChem (Impact Factor 2018: 2.641) publishes important breakthroughs across all areas at the interface of chemistry and biology, including the fields of chemical biology, bioorganic chemistry, bioinorganic chemistry, synthetic biology, biocatalysis, bionanotechnology, and biomaterials. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies, and supported by the Asian Chemical Editorial Society (ACES).